Formycon is solidifying its position in ophthalmologic follow-on products with the development of a biosimilar for aflibercept. It joins the follow-on version of ranibizumab that is already in Phase 3 clinical trials.
Powered by Steuernachrichten
AAO News Archive
- Deal struck to develop integrin antagonist treatment
- New low-add multifocal IOLs yield higher patient satisfaction
- Regeneron, Bayer to develop AMD combination therapy
- FDA approves wide-field imaging system for newborns
- Brain mapping may someday lead to vision-restoring therapies
- FDA warns of loose safety seals on eye drops
- Stem cells regrow human lens, corneal tissue
Biosimilars for aflibercept and ranibizumab in development
- Details